ID   OCM-1
AC   CVCL_6934
SY   OCM1; Ocm1; Ocular Choroidal Melanoma-1
DR   BTO; BTO:0002736
DR   cancercelllines; CVCL_6934
DR   Cosmic; 848327
DR   Cosmic; 899892
DR   Cosmic; 916139
DR   Cosmic; 986617
DR   Cosmic; 1320368
DR   Cosmic; 1628408
DR   GEO; GSM276733
DR   Wikidata; Q54931805
RX   PubMed=2722439;
RX   PubMed=8621261;
RX   PubMed=9154388;
RX   PubMed=15714118;
RX   PubMed=16772116;
RX   PubMed=17487557;
RX   PubMed=18689700;
RX   PubMed=22236444;
RX   PubMed=23849826;
RX   PubMed=28940260;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=28940260). Originally thought to originate from a female patient with uveal melanoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00502.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22236444).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
ST   Source(s): PubMed=18689700
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 13,18
ST   D21S11: 30
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 8,10
ST   D8S1179: 13
ST   FGA: 21
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=2722439;
RA   Kan-Mitchell J., Mitchell M.S., Rao N., Liggett P.E.;
RT   "Characterization of uveal melanoma cell lines that grow as xenografts
RT   in rabbit eyes.";
RL   Invest. Ophthalmol. Vis. Sci. 30:829-834(1989).
//
RX   PubMed=8621261; DOI=10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F;
RA   Luyten G.P.M., Naus N.C., Mooy C.M., Hagemeijer A., Kan-Mitchell J.,
RA   van Drunen E., Vuzevski V., de Jong P.T.V.M., Luider T.M.;
RT   "Establishment and characterization of primary and metastatic uveal
RT   melanoma cell lines.";
RL   Int. J. Cancer 66:380-387(1996).
//
RX   PubMed=9154388; DOI=10.1076/ceyr.16.5.487.7047;
RA   Diebold Y., Blanco G., Saornil-Alvarez M.A., Fernandez N., Lazaro M.C.;
RT   "Morphologic and immunocytochemical characterization of four human
RT   uveal cell lines (melanoma- and melanocytes-derived).";
RL   Curr. Eye Res. 16:487-495(1997).
//
RX   PubMed=15714118; DOI=10.1097/00008390-200502000-00006;
RA   Lopez-Velasco R., Morilla-Grasa A., Saornil-Alvarez M.A.,
RA   Ordonez J.L., Blanco G., Rabano G., Fernandez N., Almaraz A.;
RT   "Efficacy of five human melanocytic cell lines in experimental rabbit
RT   choroidal melanoma.";
RL   Melanoma Res. 15:29-37(2005).
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=17487557; DOI=10.1007/s10585-007-9072-z;
RA   Marshall J.-C., Nantel A., Blanco P., Ash J., Cruess S.R.,
RA   Burnier M.N. Jr.;
RT   "Transcriptional profiling of human uveal melanoma from cell lines to
RT   intraocular tumors to metastasis.";
RL   Clin. Exp. Metastasis 24:353-362(2007).
//
RX   PubMed=18689700; DOI=10.1167/iovs.08-2324;
RA   Folberg R., Kadkol S.S., Frenkel S., Valyi-Nagy K., Jager M.J.,
RA   Pe'er J., Maniotis A.J.;
RT   "Authenticating cell lines in ophthalmic research laboratories.";
RL   Invest. Ophthalmol. Vis. Sci. 49:4697-4701(2008).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by Gefitinib and Cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=28940260; DOI=10.1002/ijc.31067;
RA   Korch C.T., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M.,
RA   Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C.,
RA   Healy L.E., Kniss D.A., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A.,
RA   Capes-Davis A.;
RT   "Authentication of M14 melanoma cell line proves misidentification of
RT   MDA-MB-435 breast cancer cell line.";
RL   Int. J. Cancer 142:561-572(2017).
//